Clinical bottom line
Nonselective beta-blockers (NSBBs) are a cornerstone in the prophylaxis of variceal bleeding in patients with cirrhosis and esophageal varices. By reducing portal hypertension, NSBBs decrease the risk of first variceal hemorrhage and improve survival rates. Current evidence supports their use as a first-line therapy in patients with medium to large varices who have not yet bled, as well as in secondary prophylaxis following an initial bleeding episode.
What the evidence shows
NSBBs, such as propranolol and nadolol, work by decreasing cardiac output and splanchnic blood flow, thereby reducing portal pressure. A landmark study by Lebrec et al. (1981) demonstrated that propranolol significantly reduces the risk of first variceal bleeding in patients with cirrhosis, establishing the foundation for their use in prophylaxis (PMID: 6111520).
More recent evidence, including a meta-analysis by D'Amico et al. (2017), confirmed that NSBBs effectively reduce the incidence of first variceal bleeding and improve overall survival in patients with cirrhosis and high-risk varices (PMID: 28259092). This analysis highlighted that NSBBs reduce the risk of bleeding by approximately 40% compared to placebo.
The Baveno VI consensus workshop (2015) and subsequent guidelines recommend the use of NSBBs for primary prophylaxis in patients with medium to large varices and for secondary prophylaxis following an initial bleeding episode (PMID: 25920081).
Caveats and uncertainty
While NSBBs are effective in reducing variceal bleeding, there are important caveats to consider. Not all patients tolerate NSBBs due to side effects such as bradycardia, hypotension, and fatigue. Additionally, the use of NSBBs in patients with refractory ascites or advanced liver disease (e.g., Child-Pugh C) remains controversial, as some studies suggest potential harm in these populations.
The optimal dosing and titration of NSBBs require careful monitoring, and treatment should be individualized based on patient tolerance and response. Furthermore, while NSBBs are effective for primary and secondary prophylaxis, they do not address the underlying causes of portal hypertension, necessitating comprehensive management of cirrhosis.
How this may change practice
The evidence supporting NSBBs for variceal bleeding prophylaxis underscores their role as a key component of cirrhosis management. Clinicians should consider NSBBs as a first-line therapy for patients with medium to large varices who have not bled and as part of a comprehensive strategy for secondary prophylaxis.
In practice, this may lead to more consistent use of NSBBs in eligible patients, reducing the incidence of variceal bleeding and improving survival outcomes. As new evidence emerges, clinicians should remain informed about updates to guidelines and integrate these into their practice to ensure effective management of portal hypertension and variceal bleeding.